CSL announced the exit of Paul McKenzie as chief executive. Senior executive Gordon Naylor appointed interim CEO. Shares of Australian biotech firm CSL plunged to an 8-year low Wednesday after it ...

CSL's underlying earnings fell in the first half, but management stuck to its full-year guidance and boosted the buy-back. The CSL Ltd (ASX: CSL) share price is in focus today after reporting ...

Australian pharmaceuticals heavyweight CSL has announced its chief executive Dr Paul McKenzie is retiring with immediate effect, as the company tries to rebuild confidence among investors following a ...

With pressure piling on for CSL, the Australian vaccine and plasma specialist has elected to part ways with its CEO on the eve of its latest earnings announcement. Paul McKenzie, Ph.D., who’s served ...

CSL has gotten the Memo about the value of recombinant polyclonal immunoglobulin (IgG) antibodies. The company is signing on to a collaboration and option agreement with Memo Therapeutics that could ...

Given its struggles over the past couple of years, it has been tempting to sell CSL Ltd (ASX: CSL) shares on numerous occasions. However, I'm hoping to never sell the biotechnology giant's shares. The ...

Building envelope solutions provider Carlisle Companies (NYSE:CSL) will be reporting earnings this Tuesday after market close. Here’s what investors should know. Carlisle beat analysts’ revenue ...

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. If you are wondering whether ...

Madhu S Nair, Chairman and Managing Director of Cochin Shipyard Ltd (CSL), will complete his decade-long tenure on January 31, coinciding with his superannuation after more than 37 years of service ...

After spending 150 days on Princess Cruises, I earned the highest loyalty status — Elite. As an Elite member, I get access to free laundry services and discounted WiFi. I also get priority access to ...

You’d think that blasting bullets into a Nazi’s nutsack would be a thrill that never gets old, but somehow Sniper Elite: Resistance has made shooting SS scumbags squarely in their Swasticles start to ...

Nov 18 (Reuters) - Australian biotech firm CSL (CSL.AX), opens new tab said on Tuesday it would invest $1.5 billion in the U.S. to manufacture plasma-derived therapies, in a move to expand its ...